PNPLA2 and metabolic dysfunction-associated steatotic liver disease: Accordingly, the inhibition of ATGL suggested to be a therapeutic target in liver inflammation and NAFLD [2], myocardial injury [4, 5] or heart failure [6, 7] may lead to detrimental effects on endothelial function.